-
-
-
-
-
-
-
Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates
-
-
-
-
-
-
-
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
-
-
-
-
-
-
-
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
-
-
-
-
-
-
-
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
-
-
-
-
-
-
-
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
-
-
-
-
-
-
-
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
-
-
-
-
-
-
-
Pfizer, Novo again raise Metsera bids in intensifying obesity drug battle
-
1,180,150 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

